Healthcare provider profile · identity verified

Vikas Simon Mittal, MD

Hospice and Palliative Care · SAINT PAUL, MN · NPI 1629038377

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Shingrix	Varicella-Zoster Ge/As01b/Pf	272	240
Eliquis	Apixaban	225	28
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	192	192
Gabapentin	Gabapentin	156	39
Atorvastatin Calcium	Atorvastatin Calcium	147	28
Levothyroxine Sodium	Levothyroxine Sodium	147	31
Metoprolol Tartrate	Metoprolol Tartrate	135	21
Amlodipine Besylate	Amlodipine Besylate	127	28
Furosemide	Furosemide	121	37
Lisinopril	Lisinopril	120	25
Trazodone Hcl	Trazodone Hcl	116	28
Metformin Hcl	Metformin Hcl	110	19
Tamsulosin Hcl	Tamsulosin Hcl	98	22
Omeprazole	Omeprazole	97	29
Duloxetine Hcl	Duloxetine Hcl	95	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	89	18
Quetiapine Fumarate	Quetiapine Fumarate	81	25
Olanzapine	Olanzapine	79	16
Spironolactone	Spironolactone	79	21
Arexvy	Rsvpref3 Antigen/As01e/Pf	74	74
Escitalopram Oxalate	Escitalopram Oxalate	72	15
Losartan Potassium	Losartan Potassium	71	18
Pantoprazole Sodium	Pantoprazole Sodium	69	21
Potassium Chloride	Potassium Chloride	69	22
Metoprolol Succinate	Metoprolol Succinate	65	18
Famotidine	Famotidine	63	12
Mirtazapine	Mirtazapine	63	17
Oxycodone Hcl	Oxycodone Hcl	63	19
Humalog Kwikpen U-100	Insulin Lispro	62	11
Buspirone Hcl	Buspirone Hcl	61	20
Tramadol Hcl	Tramadol Hcl	61	19
Sertraline Hcl	Sertraline Hcl	56	18
Finasteride	Finasteride	53	suppressed
Divalproex Sodium	Divalproex Sodium	52	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	47	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	45	suppressed
Warfarin Sodium	Warfarin Sodium	45	suppressed
Farxiga	Dapagliflozin Propanediol	44	suppressed
Allopurinol	Allopurinol	43	suppressed
Donepezil Hcl	Donepezil Hcl	42	suppressed
Citalopram Hbr	Citalopram Hydrobromide	41	12
Midodrine Hcl	Midodrine Hcl	41	suppressed
Lamotrigine	Lamotrigine	39	suppressed
Carvedilol	Carvedilol	37	suppressed
Aripiprazole	Aripiprazole	36	13
Fluticasone Propionate	Fluticasone Propionate	36	13
Prednisone	Prednisone	36	13
Ondansetron Hcl	Ondansetron Hcl	35	13
Topiramate	Topiramate	35	suppressed
Simvastatin	Simvastatin	34	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	32	12
Bumetanide	Bumetanide	31	suppressed
Jardiance	Empagliflozin	31	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	31	suppressed
Insulin Aspart Flexpen	Insulin Aspart	30	suppressed
Nystatin	Nystatin	30	18
Oxybutynin Chloride Er	Oxybutynin Chloride	30	suppressed
Torsemide	Torsemide	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	26	suppressed
Lorazepam	Lorazepam	26	18
Novolog Flexpen	Insulin Aspart	25	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Levetiracetam	Levetiracetam	24	suppressed
Atropine Sulfate	Atropine Sulfate	23	21
Sucralfate	Sucralfate	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	21	suppressed
Cephalexin	Cephalexin	20	15
Lactulose	Lactulose	20	suppressed
Methadone Hcl	Methadone Hcl	20	suppressed
Amiodarone Hcl	Amiodarone Hcl	19	suppressed
Hydrocortisone	Hydrocortisone	19	suppressed
Morphine Sulfate	Morphine Sulfate	19	17
Carbidopa-Levodopa	Carbidopa/Levodopa	18	suppressed
Divalproex Sodium Er	Divalproex Sodium	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Risperidone	Risperidone	18	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	18	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	17	12
Clindamycin Hcl	Clindamycin Hcl	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	suppressed
Lubiprostone	Lubiprostone	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Timolol Maleate	Timolol Maleate	17	suppressed
Atenolol	Atenolol	16	suppressed
Haloperidol	Haloperidol	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Baclofen	Baclofen	15	suppressed
Diazepam	Diazepam	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	14	suppressed
Bupropion Hcl	Bupropion Hcl	13	suppressed
Lurasidone Hcl	Lurasidone Hcl	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Valproic Acid	Valproic Acid	13	suppressed
Albuterol Sulfate	Albuterol Sulfate	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Ozempic	Semaglutide	12	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Benztropine Mesylate	Benztropine Mesylate	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error